Nosocomial and Ventilator-Associated Pneumonia
 |
|
 For decades, ventilator-associated pneumonia (VAP) has been thought to be the most important complication of intensive care medicine. A meta-analysis of studies published in the 1990s calculated the incidence of VAP, which is equivalent to 16.5 cases per 1,000 patient days. Attributable mortality due to VAP was estimated to be 20–40%, although the range in different studies was very broad. Healthcare costs realted to VAP seem to be remarkable, in particular with regard to multidrug-resistant pathogens. A controversial debate about the management of VAP occurred in the literature at the beginning of the century, but latterly the discussion has wound down. The latest VAP guidelines were published in 2005 by the American Thoracic Society/Infectious Diseases Society of America, and a consensus paper was published in in 2009; however, the number of VAP studies has decreased dramatically. | | Nosocomial and Ventilator-Associated Pneumonia (Issue 53) | |
| Guest Editors
Eur Respir Mon 2011; 53: v |  |  | | | | | | | | | | | Preface
Eur Respir Mon 2011; 53: vi | | | | | | | | | | | | | Introduction
Torres A., Ewig S.
Eur Respir Mon 2011; 53: vii | | | | | | | | | | | | | Aetiopathogenesis of VAP revisited  (1 grade, 0 comment)
Aya B H.D., Rello J.
Eur Respir Mon 2011; 53: 1-10 | | |  | | | | | | | | | | New approaches to the aetiological diagnosis of VAP
Bouza E., Burillo A., Cercenado E.
Eur Respir Mon 2011; 53: 11-23 | | | | | | | | | | | | | Biomarkers and VAP: results and perspectives
Torres A., Ewig S.
Eur Respir Mon 2011; 53: 24-35 | | | | | | | | | | | | | VAP: approach to therapy
Niederman M.S.
Eur Respir Mon 2011; 53: 36-47 | | | | | | | | | | | | | New antibiotics for VAP
Wunderink R.G.
Eur Respir Mon 2011; 53: 48-53 | | | | | | | | | | | | | Aerosolised treatment for VAP
Luyt C-E., Combes A., Nieszkowska A., Trouillet J-L., Chastre J.
Eur Respir Mon 2011; 53: 54-65 | | | | | | | | | | | | | Impact of guidelines on HAP and VAP outcomes
Torres A., Ferrer M., Amaro R., López-Giraldo A.
Eur Respir Mon 2011; 53: 66-73 | | | | | | | | | | | | | VAP prevention: pharmacological strategies
Morrow L.E., Kollef M.H.
Eur Respir Mon 2011; 53: 74-82 | | | | | | | | | | | | | VAP prevention:non-pharmacological strategies
Valencia M., Li Bassi G., Torres A.
Eur Respir Mon 2011; 53: 83-97 | | | | | | | | | | | | | Animal models of VAP
Bruno D., García-Morato J., Luna C.M.
Eur Respir Mon 2011; 53: 98-112 | | | | | | | | | | | | | Viral VAP
Luyt C-E., Combes A., Nieszkowska A., Trouillet J-L., Chastre J.
Eur Respir Mon 2011; 53: 113-121 | | | | | | | | | | | | | Fungal VAP
Ewig S., Tasci S., Müller E.
Eur Respir Mon 2011; 53: 122-137 | | | | | | | | | | | | | HAP in nonventilated patients
Sabrià M., Sopena N.
Eur Respir Mon 2011; 53: 138-150 | | | | | | | | | | | | | Ventilator-associated tracheobronchitis
Nseir S.
Eur Respir Mon 2011; 53: 151-159 | | | | | | | | | | | |
|
|
WHAT YOU CAN FIND HERE  |
 |
Full text journal article |
 |
PDF journal article |
 |
Journal article abstract |
|
|
|